Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.

In another clinical trial conducted in children with high-risk or first-relapsed B-ALL, even patients with MRD less than 0.01% showed a trend of benefiting from blinatumomab when compared with traditional chemotherapy, indicating that deeper MRD must be eradicated to prevent relapse 9 .

also in 53,322 other papers

Regarding the genetic features, patients with different fusion genes seemed to respond differently to induction therapy, but the multiple comparisons between different fusion genes did not reach statistical significance at EOI.

also in 111,027 other papers